Subsequent Events (Detail Textuals) - USD ($)
|
1 Months Ended |
12 Months Ended |
|
|
|
Dec. 20, 2019 |
Dec. 19, 2019 |
Nov. 20, 2019 |
Feb. 28, 2019 |
Feb. 01, 2019 |
Jan. 31, 2019 |
Feb. 16, 2018 |
Jan. 19, 2018 |
Dec. 31, 2017 |
Sep. 30, 2019 |
Dec. 31, 2018 |
Mar. 31, 2017 |
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Value of warrants issued |
|
|
|
|
|
|
|
|
$ 145,200
|
|
|
|
| Par value of common stock issued |
|
|
|
|
|
|
|
|
$ 0.001
|
$ 0.001
|
$ 0.001
|
$ 0.001
|
| Securities Purchase Agreement | Emerald Health Sciences Inc |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued |
|
|
|
|
|
|
15,000,000
|
15,000,000
|
|
|
|
|
| Number of warrants issued |
|
|
|
|
|
|
20,400,000
|
20,400,000
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
|
|
$ 0.10
|
$ 0.10
|
|
|
|
|
| Term of warrant |
|
|
|
|
|
|
5 years
|
|
|
|
|
|
| Subsequent Event | Pharmaceuticals International, Inc. Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated initial payment for contract |
|
|
|
|
|
$ 72,500
|
|
|
|
|
|
|
| Subsequent Event | RRD International Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Amount of payments due under the contract |
|
|
|
|
|
78,680
|
|
|
|
|
|
|
| Amount of pass through expenses and consulting fees |
|
|
|
|
|
$ 22,000
|
|
|
|
|
|
|
| Subsequent Event | 2nd Draw on Multi Draw Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Value of warrants issued |
|
|
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
| Number of warrants issued |
|
|
|
|
2,500,000
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
$ 0.50
|
|
|
|
|
|
|
|
| Subsequent Event | Noramco Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront payment |
|
|
|
$ 146,386
|
|
|
|
|
|
|
|
|
| Subsequent Event | Independent Contractor Services Agreement | Dr. Avtar Dhillon |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Monthly fee |
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
| Monthly fee paid each month |
|
5,000
|
|
|
|
|
|
|
|
|
|
|
| Monthly fee accruing from effective date |
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event | Warrant Exercise Agreement | Emerald Health Sciences Inc |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants exercised |
40,800,000
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate exercise price of warrants |
$ 4,080,000
|
|
|
|
|
|
|
|
|
|
|
|
| Remaining balance of credit facility |
$ 2,014,500
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event | Securities Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Gross offering price for sale of securities |
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
| Common stock issued |
|
|
8,000,000
|
|
|
|
|
|
|
|
|
|
| Par value of common stock issued |
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
| Sale of stock, price per share |
|
|
$ 0.25
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued |
|
|
8,000,000
|
|
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
$ 0.35
|
|
|
|
|
|
|
|
|
|
| Term of warrant |
|
|
5 years
|
|
|
|
|
|
|
|
|
|